Xvivo Perfusion (XVIVO) Stock Overview
A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XVIVO Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Xvivo Perfusion AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 164.90 |
| 52 Week High | SEK 519.00 |
| 52 Week Low | SEK 162.10 |
| Beta | 2.01 |
| 1 Month Change | -0.84% |
| 3 Month Change | -43.60% |
| 1 Year Change | -66.28% |
| 3 Year Change | 20.54% |
| 5 Year Change | -35.08% |
| Change since IPO | 767.89% |
Recent News & Updates
Recent updates
These Analysts Just Made A Massive Downgrade To Their Xvivo Perfusion AB (publ) (STO:XVIVO) EPS Forecasts
Jul 17
Earnings Miss: Xvivo Perfusion AB (publ) Missed EPS And Analysts Are Revising Their Forecasts
Jul 14Xvivo Perfusion AB (publ)'s (STO:XVIVO) 37% Cheaper Price Remains In Tune With Earnings
Jul 12Xvivo Perfusion (STO:XVIVO) Is Doing The Right Things To Multiply Its Share Price
Jun 20Xvivo Perfusion AB (publ)'s (STO:XVIVO) Intrinsic Value Is Potentially 36% Above Its Share Price
Apr 03
Success Of US Heart Trial Will Strengthen Position In Heart Transplantation Market
Strategic acquisitions and production scaling are anticipated to enhance sales growth, operational efficiency, and improve gross margin profitability.Market Participants Recognise Xvivo Perfusion AB (publ)'s (STO:XVIVO) Earnings
Mar 10Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jan 31Xvivo Perfusion (STO:XVIVO) Is Experiencing Growth In Returns On Capital
Jan 30Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 43% Undervaluation?
Dec 06Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 04Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Oct 27With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For
Oct 25Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?
Aug 03Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Apr 25There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital
Apr 11Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates
Feb 05We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings
Feb 01Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jan 28Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled
Aug 24Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching
Jul 17Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?
Jun 16Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital
Apr 19Shareholder Returns
| XVIVO | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -5.3% | 1.4% | 2.7% |
| 1Y | -66.3% | -19.2% | -1.2% |
Return vs Industry: XVIVO underperformed the Swedish Medical Equipment industry which returned -19.9% over the past year.
Return vs Market: XVIVO underperformed the Swedish Market which returned -1.7% over the past year.
Price Volatility
| XVIVO volatility | |
|---|---|
| XVIVO Average Weekly Movement | 10.7% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: XVIVO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: XVIVO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 193 | Christoffer Rosenblad | www.xvivogroup.com |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient.
Xvivo Perfusion AB (publ) Fundamentals Summary
| XVIVO fundamental statistics | |
|---|---|
| Market cap | SEK 5.19b |
| Earnings (TTM) | SEK 111.38m |
| Revenue (TTM) | SEK 822.93m |
Is XVIVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XVIVO income statement (TTM) | |
|---|---|
| Revenue | SEK 822.93m |
| Cost of Revenue | SEK 206.83m |
| Gross Profit | SEK 616.09m |
| Other Expenses | SEK 504.72m |
| Earnings | SEK 111.38m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 23, 2025
| Earnings per share (EPS) | 3.54 |
| Gross Margin | 74.87% |
| Net Profit Margin | 13.53% |
| Debt/Equity Ratio | 0% |
How did XVIVO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 07:51 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xvivo Perfusion AB (publ) is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Erik Cassel | Danske Bank |
| Daniel Albin | Danske Bank |